Zimbabwe has turned down a significant US health deal valued at $367m (£272m) spanning five years because of Washington's insistence on confidential data.
The decision came to light following a official document from December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "lopsided".
An official spokesperson later clarified that the US was requesting health data for research and commercial purposes while refused to share the resulting advantages from future treatments.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had provided more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged more talks to find a agreement agreeable to both sides so the country's critical HIV treatment initiative can continue.
Wider Background
This rejection follows a similar case in Kenya, where a high court halted a similar health funding agreement following legal challenges were raised about the safety of citizens' health data.
Since resuming office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen aid for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government agreements to enhance transparency and accountability.
According to statements, 16 African countries have to date agreed to similar agreements, constituting over $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered significant advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment via US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to provide its biological resources and data over an extended period, without any equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery without any certainty that the resulting innovations would be accessible to our citizens should a future pandemic arise."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting structures already set up via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This mechanism is intended to guarantee that when a country contributes its data, the benefits – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," he added.
"We encourage further discussions with our US partners on how future co-operation might be designed in a manner that honours the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but recommended that talks need to persist given that a large portion of the nation's Aids initiatives relied on international support.
"Where technical issues arise, including those involving data governance or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," the group added.
This impasse underscores the continuing debate between receiving much-needed foreign assistance and protecting local interests in an increasingly data-driven world.